Immune Design to Report First Quarter 2017 Financial Results & Provide Corporate Update

SEATTLE and SOUTH SAN FRANCISCO, Calif., May 08, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report first quarter 2017 financial results and provide a corporate update after the close of U.S. financial markets on Wednesday, May 17, 2017. Immune Design management will host a webcast and conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on May 17, 2017.

The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for 30 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 20090178.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases.  CMB305 and G100, the primary foci of Immune Design's ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex^® and GLAAS^®.  Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

Media Contact
Julie Rathbun
Rathbun Communications
[email protected]                  
206-769-9219

Investor Contact
Shari Annes
Annes Associates
[email protected]
650-888-0902